Literature DB >> 1773095

Melatonin administration to blind people: phase advances and entrainment.

R L Sack1, A J Lewy, M L Blood, J Stevenson, L D Keith.   

Abstract

The purpose of this study was to test the phase-shifting and entraining effects of melatonin in human subjects. Five totally blind men were found in a previous study to have free-running endogenous melatonin rhythms. Their rhythms were remarkably stable, so that any deviation from the predicted phase was readily detectable. After determination of their free-running period and phase, they were given exogenous melatonin (5 mg) at bedtime (2200 hr) for 3 weeks, in a double-blind, placebo-controlled trial. The effects on the endogenous melatonin rhythm were assessed at intervals ranging from several days to 2 weeks. Exogenous administration of melatonin phase-advanced their endogenous melatonin rhythms. In three of the subjects, cortisol was shown to be phase-shifted in tandem with the melatonin rhythm. A sixth subject [one of the coauthors (JS)] was previously found to have free-running cortisol and temperature rhythms and was plagued by recurrent insomnia and daytime sleepiness. He had tried unsuccessfully to entrain his rhythms for over 10 years. After he took melatonin (7 mg at 2100 hr), his insomnia and sleepiness resolved. Determination of his endogenous melatonin rhythm after about a year of treatment demonstrated endogenous rhythms that appeared normally entrained. The treatment of blind people with free-running rhythms has many advantages for demonstrating chronobiological effects of hormones or drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1773095     DOI: 10.1177/074873049100600305

Source DB:  PubMed          Journal:  J Biol Rhythms        ISSN: 0748-7304            Impact factor:   3.182


  24 in total

1.  Circadian Rhythm Sleep Disorders.

Authors:  Min Ju Kim; Jung Hie Lee; Jeanne F Duffy
Journal:  J Clin Outcomes Manag       Date:  2013-11-01

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 3.  The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies.

Authors:  S McGaffigan; D L Bliwise
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

Review 4.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Potential of melatonin replacement therapy in older patients with sleep disorders.

Authors:  I Haimov; P Lavie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

6.  Use of slow-release melatonin in treatment-resistant depression.

Authors:  E J Dalton; D Rotondi; R D Levitan; S H Kennedy; G M Brown
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

Review 7.  Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.

Authors:  Jonathan S Emens; Charmane I Eastman
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 8.  Circadian regulation of pineal gland rhythmicity.

Authors:  Jimo Borjigin; L Samantha Zhang; Anda-Alexandra Calinescu
Journal:  Mol Cell Endocrinol       Date:  2011-07-18       Impact factor: 4.102

9.  Effect of pharmacological daytime doses of melatonin on human mood and performance.

Authors:  A B Dollins; H J Lynch; R J Wurtman; M H Deng; K U Kischka; R E Gleason; H R Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 10.  Light, melatonin and the sleep-wake cycle.

Authors:  G M Brown
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.